×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 3.8% decline adds to one-year losses, institutional investors may consider drastic measures
Simply Wall Street
Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to...
19 hours ago
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Yahoo Finance
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing...
3 days ago
Intellia, Aera the latest gene editing biotechs to lay off staff
Fierce Biotech
Intellia Therapeutics is the latest gene editing biotech to downsize following a dismal year for the industry.
3 months ago
Intellia Therapeutics doses first patient in pivotal in vivo CRISPR trial
Clinical Trials Arena
Intellia Therapeutic's NTLA-2001 is the first in vivo CRISPR candidate to make late-stage trials.
1 month ago
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Zacks Investment Research
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming...
4 days ago
Intellia Therapeutics Ends Co-Development Agreement With Regeneron
Morningstar
Intellia Therapeutics Ends Co-Development Agreement With Regeneron ... Intellia Therapeutics said in a filing that it has notified Regeneron...
1 month ago
Better Cathie Wood Stock: Moderna vs. Intellia
The Motley Fool
The idea is to buy promising companies for a good price and hold onto the shares for a number of years -- giving those companies time to bring...
1 month ago
Intellia propels into 2024 with CRISPR pipeline updates
Pharmaceutical Technology
The Massachusetts-headquartered company announced its 2024 aim to complete patient enrolment for studies evaluating NTLA-2001 and NTLA-2002.
3 months ago
First Week of June 21st Options Trading For Intellia Therapeutics (NTLA)
Nasdaq
Investors in Intellia Therapeutics Inc (Symbol: NTLA) saw new options become available this week, for the June 21st expiration.
1 week ago
Intellia plays down concerns about accidental germline transmission in CRISPR trial
STAT
It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in...
8 months ago